ESMO 2024 Highlights Webinar-ESMO 2024 Highlights Webinar

Video Transcription

Video Summary

The ESLC webinar "ESMO 2024 Highlights" covers recent advancements in lung cancer treatment, focusing on both non-small cell lung cancer (NSCLC) and small cell lung cancer. Dr. Michele Aldea and Francesco Pasiglia led discussions on emerging research, trials, and treatment regimens presented at ESMO 2024.<br /><br />Dr. Silvia Novello presented on early-stage NSCLC, including insights into adjuvant, neoadjuvant, and perioperative settings. She emphasized the need for biomarker-driven studies to pinpoint patients who would benefit from neoadjuvant chemotherapy-free immunotherapy.<br /><br />Professor Benjamin Best discussed metastatic NSCLC, highlighting recent trials for innovative therapies, including those targeting EGFR mutations, ALK inhibitors, and ROS1-positive cancers. He stressed the need for combining molecular and PD-L1 status to determine treatment paths and discussed challenges with new antibody-drug conjugates.<br /><br />Dr. Ross Soh focused on small cell lung cancer and thymic epithelial tumors, examining trials like Adriatic and therapies combining pembrolizumab with lenvatinib, which showed promise in progression-free survival among certain cancer types.<br /><br />The webinar concluded with a Q&A, addressing questions about the future of lung cancer treatments and strategies for patients with rare driver mutations or those relapsing after standard regimens.

Keywords

ESMO 2024 Highlights

lung cancer treatment

NSCLC

small cell lung cancer

biomarker-driven studies

EGFR mutations

antibody-drug conjugates

pembrolizumab lenvatinib

rare driver mutations